June 6, 2025

Altimmune, Inc. (ALT) Stock Analysis: Unlocking a 277.75% Potential Upside in Biotech

Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, is attracting significant attention from investors, particularly due to its bold foray into the treatment of obesity and metabolic diseases. With a..

Autolus Therapeutics plc (AUTL) Stock Analysis: Harnessing a 341% Potential Upside in Biotech Innovation

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company based in the United Kingdom, is capturing the attention of investors with its transformative approach to cancer and autoimmune disease treatments...

Abivax SA (ABVX) Stock Analysis: Unlocking a Potential 355% Upside in Biotechnology

Abivax SA (ABVX), a prominent player in the biotechnology sector, is grabbing the spotlight with a potential upside of 355.74%, according to analysts’ target price projections. Headquartered in Paris, France,..

Maze Therapeutics, Inc. (MAZE) Investor Outlook: An 87% Upside Potential in Biotech Innovation

Maze Therapeutics, Inc. (MAZE), a burgeoning entity within the biotechnology sector, is capturing attention with its compelling growth potential and strategic focus on precision medicines. With a market capitalization of..

Sage Therapeutics, Inc. (SAGE) Investor Outlook: Analyzing the 21% Potential Upside in Biotech

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biotech firm specializing in brain health medicines, has recently captured investor attention due to its intriguing potential upside. The company, headquartered in Cambridge, Massachusetts,..

Regulus Therapeutics Inc. (RGLS) Stock Analysis: Navigating Biotech’s Frontier with a Promising 8.64% Potential Upside

Regulus Therapeutics Inc. (RGLS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to drug discovery. Specializing in targeting microRNAs to treat a variety..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 337% Potential Upside in the Biotechnology Arena

Relay Therapeutics, Inc. (NASDAQ: RLAY) has been a subject of interest within the biotechnology sector, offering a compelling narrative for investors seeking opportunities in precision medicine. This clinical-stage company, headquartered..

Claritev Corporation (CTEV) Stock Analysis: Navigating a 52-Week High Despite Financial Headwinds

Claritev Corporation (NASDAQ: CTEV) stands as a prominent player within the healthcare sector, specifically in the realm of health information services. With a market capitalization of $631.16 million, this New..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 123% Potential Upside in the Biotech Sector

Emergent BioSolutions Inc. (NYSE: EBS) presents a compelling opportunity for investors seeking high-risk, high-reward plays in the healthcare sector. With a market capitalization of $328.38 million, this U.S.-based life sciences..

Sana Biotechnology, Inc. (SANA) Stock Analysis: A 266% Upside Potential in the Biotech Sector

Sana Biotechnology, Inc. (NASDAQ: SANA), a promising player in the biotech landscape, is capturing the attention of investors with a staggering potential upside of 266.01%. The company, headquartered in Seattle,..

Talkspace, Inc. (TALK) Stock Analysis: Exploring a 53.85% Potential Upside

Talkspace, Inc. (NASDAQ: TALK) is drawing considerable attention from investors, thanks to its solid potential upside of 53.85% as indicated by recent analyst ratings. This New York-based healthcare company is..

Celcuity Inc. (CELC) Stock Analysis: Impressive 141.94% Potential Upside in Biotechnology Sector

Celcuity Inc. (NASDAQ: CELC), a notable player in the biotechnology sector, is capturing investor attention with a remarkable potential upside of 141.94%. This clinical-stage biotech firm, headquartered in Minneapolis, focuses..

REGENXBIO Inc. (RGNX) Investor Outlook: Unveiling a 279.78% Potential Upside with Robust Revenue Growth

REGENXBIO Inc. (RGNX), a pioneer in gene therapy, is capturing the attention of investors with its impressive 279.78% potential upside, backed by substantial revenue growth. As a clinical-stage biotechnology company,..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: A Biotech with a 145.91% Potential Upside

Investors with an interest in the biotechnology sector may want to pay close attention to Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a company with an ambitious portfolio and promising market outlook...

Organogenesis Holdings Inc. (ORGO) Stock Analysis: A 117% Potential Upside Awaits Investors

Investors seeking opportunities in the healthcare sector might find Organogenesis Holdings Inc. (NASDAQ: ORGO) to be an intriguing contender, particularly given its substantial potential upside. Specializing in regenerative medicine, Organogenesis..

ATAI Life Sciences (ATAI) Stock Analysis: Exploring a 222% Potential Upside in the Biotech Arena

ATAI Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company headquartered in Berlin, Germany, is making waves in the biotechnology sector with a remarkable potential upside of 222.58%. Trading at..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 54.78% Potential Upside Amidst Market Volatility

Myriad Genetics, Inc. (NASDAQ: MYGN) presents an intriguing investment opportunity within the healthcare sector, specifically the diagnostics and research industry. With a market capitalization of approximately $453.51 million, Myriad Genetics..

Fulgent Genetics, Inc. (FLGT) Investor Outlook: Navigating Growth Potential Amidst a Challenging Market

Fulgent Genetics, Inc. (NASDAQ: FLGT) presents a compelling case for investors interested in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $633.84 million,..

Kamada Ltd. (KMDA): Investor Outlook with 117.55% Potential Upside

Kamada Ltd. (NASDAQ: KMDA), a prominent player in the healthcare sector, specifically within the drug manufacturing industry, is catching the eye of investors with an impressive potential upside of 117.55%...

Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 154.85% Potential Upside in the Biotech Sector

Verastem, Inc. (NASDAQ: VSTM) is capturing investor attention with its ambitious pipeline in the oncology space and a striking potential upside of 154.85%, according to the latest analyst ratings. As..

Search

Funds

June 6, 2025

Search

Funds

June 6, 2025

FTSE 100

Funds